
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Cara Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

140755109

(CUSIP Number)

January 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Ascent Biomedical Ventures I, L.P.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER Not applicable
	6	SHARED VOTING POWER 963,896
	7	SOLE DISPOSITIVE POWER Not applicable
	8	SHARED DISPOSITIVE POWER 963,896
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 963,896	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) <input checked="" type="checkbox"/> (1)	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.3%	
12	TYPE OF REPORTING PERSON (See Instructions) PN	

(1) See footnote to Item 4 herein.

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Ascent Biomedical Ventures I Annex, L.P.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER Not applicable
	6	SHARED VOTING POWER 105,730
	7	SOLE DISPOSITIVE POWER Not applicable
	8	SHARED DISPOSITIVE POWER 105,730
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 105,730	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) <input checked="" type="checkbox"/> (2)	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.4%	
12	TYPE OF REPORTING PERSON (See Instructions) PN	

(2) See footnote to Item 4 herein.

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Ascent Biomedical Ventures I NY, L.P.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER Not applicable
	6	SHARED VOTING POWER 604,428
	7	SOLE DISPOSITIVE POWER Not applicable
	8	SHARED DISPOSITIVE POWER 604,428
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 604,428	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) <input checked="" type="checkbox"/> (3)	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.7%	
12	TYPE OF REPORTING PERSON (See Instructions) PN	

(3) See footnote to Item 4 herein.

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	ABV, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER Not applicable
	6	SHARED VOTING POWER 1,674,054 (4)
	7	SOLE DISPOSITIVE POWER Not applicable
	8	SHARED DISPOSITIVE POWER 1,674,054 (4)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,674,054 (4)	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) x (5)	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4%	
12	TYPE OF REPORTING PERSON (See Instructions) OO	

(4) Comprised of shares of common stock held by Ascent Biomedical Ventures I, L.P., Ascent Biomedical Ventures I Annex, L.P. and Ascent Biomedical Ventures I NY, L.P, of which ABV, LLC is the general partner.

(5) See footnote to Item 4 herein.

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Geoffrey W. Smith	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER Not applicable
	6	SHARED VOTING POWER 1,674,054 (6)
	7	SOLE DISPOSITIVE POWER Not applicable
	8	SHARED DISPOSITIVE POWER 1,674,054 (6)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,674,054 (6)	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) <input checked="" type="checkbox"/> (7)	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4%	
12	TYPE OF REPORTING PERSON (See Instructions) IN	

(6) Comprised of shares of common stock held by Ascent Biomedical Ventures I, L.P., Ascent Biomedical Ventures I Annex, L.P. and Ascent Biomedical Ventures I NY, L.P.

(7) See footnote to Item 4 herein.

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Steve Hochberg	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) <input type="radio"/> (b) <input checked="" type="radio"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER Not applicable
	6	SHARED VOTING POWER 1,674,054 (8)
	7	SOLE DISPOSITIVE POWER Not applicable
	8	SHARED DISPOSITIVE POWER 1,674,054 (8)
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,674,054 (8)	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) <input checked="" type="checkbox"/> (9)	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4%	
12	TYPE OF REPORTING PERSON (See Instructions) IN	

(8) Comprised of shares of common stock held by Ascent Biomedical Ventures I, L.P., Ascent Biomedical Ventures I Annex, L.P. and Ascent Biomedical Ventures I NY, L.P.

(9) See footnote to Item 4 herein.

Item 1.

(a) Name of Issuer:

Cara Therapeutics, Inc.

(b) Address of Issuer's Principal Executive Offices:

1 Parrott Drive, Shelton, Connecticut 06484

Item 2.

(a) Name of Person Filing:

(i) Ascent Biomedical Ventures I, L.P. ("Ascent")

(ii) Ascent Biomedical Ventures I Annex, L.P. ("Ascent Annex")

(iii) Ascent Biomedical Ventures I NY, L.P. ("Ascent NY")

(iv) ABV, LLC ("ABV")

(v) Geoffrey W. Smith ("Geoffrey Smith")

(vi) Steve Hochberg ("Steve Hochberg" and together with Ascent, Ascent Annex, Ascent NY, ABV, and Geoffrey Smith, the "Reporting Persons")

(b) Address of Principal Business Office or, if none, Residence:

(i) 142 West 57th Street, 4A, New York, NY 10019

(ii) 142 West 57th Street, 4A, New York, NY 10019

(iii) 142 West 57th Street, 4A, New York, NY 10019

(iv) 142 West 57th Street, 4A, New York, NY 10019

(v) 142 West 57th Street, 4A, New York, NY 10019

(vi) 142 West 57th Street, 4A, New York, NY 10019

(c) Citizenship:

(i) Delaware limited liability partnership

(ii) Delaware limited liability partnership

(iii) Delaware limited liability partnership

(iv) Delaware limited liability company

(v) United States Citizen

(vi) United States Citizen

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

140755109

Item 3.

Not applicable.

Item 4. Ownership.

(a) Amount Beneficially Owned**:

The responses of the Reporting Persons to Rows (9) through (10) of the cover pages of this Statement are incorporated herein by reference.

(b) Percent of Class**:

The responses of the Reporting Persons to Row (11) of the cover pages of this Statement are incorporated herein by reference.

(c) Number of shares as to which the person has**:

The responses of the Reporting Persons to Rows (5) through (8) of the cover pages of this Statement are incorporated herein by reference.

ABV is the general partner of Ascent, Ascent Annex and Ascent NY. The directors of ABV are Geoffrey Smith and Steve Hochberg.

**See footnotes on cover pages which are incorporated by reference herein. The shares reported herein do not include an aggregate of 350,000 shares of common stock of the Issuer held by the individuals and entities listed on Exhibit B hereto, which individuals and entities are not reporting persons hereunder but may be deemed to constitute a group for purposes of Section 13(d)(3) under the Exchange Act of 1934, with the Reporting Persons. The Reporting Persons disclaim beneficial ownership over the shares held by the individuals and entities listed on Exhibit B hereunder and disclaim the existence of a group with such individuals and entities.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Member of the Group.

See Exhibit B.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Material to be Filed as Exhibits.

Exhibit A: Joint Filing Agreement

Exhibit B: Item 8 Statement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2014

ASCENT BIOMEDICAL VENTURES I, L.P.

By: ABV, LLC
its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ASCENT BIOMEDICAL VENTURES I ANNEX, L.P.

By: ABV, LLC
its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ASCENT BIOMEDICAL VENTURES I NY, L.P.

By: ABV, LLC
its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ABV, LLC

/s/ Steve Hochberg

Signature

Director

Name/Title

GEOFFREY W. SMITH

/s/ Geoffrey W. Smith

Signature

STEVE HOCHBERG

/s/ Steve Hochberg

Signature



Exhibit A

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees that the statement on Schedule 13G filed herewith shall be filed on behalf of each of the undersigned and further agrees that this joint filing agreement be included as an exhibit to this Schedule 13G. In evidence thereof, the undersigned hereby execute this Agreement as of February 10, 2014.

ASCENT BIOMEDICAL VENTURES I, L.P.

By: ABV, LLC
its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ASCENT BIOMEDICAL VENTURES I ANNEX, L.P.

By: ABV, LLC
its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ASCENT BIOMEDICAL VENTURES I NY, L.P.

By: ABV, LLC
its general partner

/s/ Steve Hochberg

Signature

Director

Name/Title

ABV, LLC

/s/ Steve Hochberg

Signature

Director

Name/Title

GEOFFREY W. SMITH

/s/ Geoffrey W. Smith

Signature

STEVE HOCHBERG

/s/ Steve Hochberg

Signature

Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934 with one another as well as with the other entities listed below. The reporting persons hereunder disclaim beneficial ownership over the shares held by the individuals and entities listed below and disclaim the existence of a group with such individuals and entities.

The aggregate number of shares held by the entities listed below is 350,000. The following is a listing of the entities along with their respective beneficial ownership amounts.

<u>Name</u>	<u>Amount Beneficially Owned</u>
James E. Flynn (1)	350,000
Deerfield Mgmt, L.P. (1)	350,000
Deerfield Management Company, L.P. (1)	350,000
Deerfield Special Situations Fund, L.P.	193,200
Deerfield Special Situations International Master Fund, L.P.	156,800

(1) Comprised of shares held by Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P.

Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P. Deerfield Management Company, L.P. is the investment advisor of Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.

Steve Hochberg is a limited partner of Deerfield Mgmt, L.P.

Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Special Situations Fund, L.P. are Delaware limited partnerships.

Deerfield Special Situations International Master Fund, L.P. is a British Virgin Islands limited partnership.

James E. Flynn is a United States citizen.

The principal address of James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P. is 780 Third Avenue, 37th Floor, New York, NY 10017.
